ANNORA PHARMA PRIVATE LIMITED
Location
Telangana
Founded
2015-11-26
Website
Risk Signals
2 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Guided Missile Space Vehicle Parts and Auxiliary Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about ANNORA PHARMA PRIVATE LIMITED
Live alerts from global media, monitored by Business Radar
2025-03-27 (tradingview.com)
Rigel climbs on blood disorder drug patent settlement — News
** Shares of drugmaker Rigel Pharmaceuticals NASDAQ:RIGL rise ~3% to $19.54** RIGL says it has settled patent litigation with Annora Pharma regarding co's blood disorder drug, Tavalisse, to treat patients with immune thrombocytopenia (ITP) who haven't responded adequately to prior treatments** Laws…
Read more
2025-03-27 (nasdaq.com)
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma |
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) Thursday announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. resolving patent litigation related to Rigel's product Tavalisse (fostamatinib disodium hexahy
Read more
2023-08-16 (bloomberglaw.com)
UCB Wins Patent Order Blocking Copies of Briviact Epilepsy Drug
UCB SA won a decision blocking copies of Briviact until 2026, as a federal judge upheld the validity of a patent three generic-drug makers had conceded their proposed versions of the epilepsy treatment infringe.
Read more
(tipranks.com)
BioCryst Faces Patent Challenge Amidst Strong Growth - TipRanks.com
BioCryst ( ($BCRX) ) has issued an announcement. In January 2025, BioCryst received a notice from Annora Pharma, challenging the patents of its drug ORLADEYO, with ...
Read more